TheStreet home
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTCRYPTOMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTERTECHNOLOGY
Search

LATEST NEWS

Biotech String: Editas IPO Terms, Rooting for Shkreli in DC
STOCKS

Biotech Stock Mailbag Readers' Portfolio: Update

Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug
STOCKS

Biotech Stock Mailbag Readers' Portfolio: Update

Germany Slaps PTC Therapeutics With Big Drug Price Cut
STOCKS

Biotech Stock Mailbag: Myriad Genetics

STOCKS

Antisoma Cancer Drug Fails Test: BioBuzz

Novartis Commits $500 Million to Russia
STOCKS

Medivation: Biotech Stock Mailbag

XBiotech Cancer Drug Survival Claim Falls Apart Under Scrutiny
STOCKS

Biotech Stock Mailbag: BioSante Pharma

Novartis Commits $500 Million to Russia
STOCKS

Biotech Stock Mailbag: Rexahn Pharma

Endo International Tumbles as Insys Expects Weak Painkiller Sales
STOCKS

Osiris CEO Flogs Failed Drug: BioBuzz

A Letter to Cel-Sci's Geert and Max
STOCKS

Novelos Falls on Failed Study: BioBuzz

XBiotech Cancer Drug Survival Claim Falls Apart Under Scrutiny
STOCKS

Biotech Stock Mailbag: Soligenix

NewLink Pancreatic Cancer Vaccine Fails, May Even Harm Patients
STOCKS

10 Biotech Stocks on Clinical Trials Watch

Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug
STOCKS

Biotech Stock Mailbag Readers' Portfolio

STOCKS

Digging Deeper Into Adventrx Pharmaceuticals

Biotech String: Editas IPO Terms, Rooting for Shkreli in DC
STOCKS

Biotech Stock Mailbag: Adventrx Pharmaceuticals

STOCKS

Biotech Stock Mailbag: Novelos Therapeutics

Chiasma Craters on FDA Drug Rejection
STOCKS

Biotech Mailbag: Cel-Sci, BioElectronics

Galena Craters on Breast Cancer Vaccine Study Failure
STOCKS

Biotech Mailbag: Cel-Sci, BioElectronics

Chiasma Craters on FDA Drug Rejection
STOCKS

Biotech Mailbag: Cel-Sci, BioElectronics

Germany Slaps PTC Therapeutics With Big Drug Price Cut
STOCKS

Biotech Mailbag: No Stem-Cell Gold Mine